SFI003 is a SRSF3 inhibitor that drives CRC cell apoptosis via the SRSF3/DHCR24/ROS axis and exhibits potent antitumor effects both in vitro and in vivo.
SFI003 (0-50 μM, 0-72 h) inhibits the proliferation of HCT116 and SW480 cells in a dose- and time-dependent manner with IC50values of 8.78 µM and 48.67 µM, respectively[1].SFI003 (0-50 μM, 24-72 h) induces apoptosis in HCT-116 and SW480 cells[1].SFI003 (0-50 μM, 24-72 h) induces ROS generation in both HCT-116 and SW480 cells in a dose-dependent manner[1].
SFI003 (p.o., 100, 200 mg/kg; for 2 consecutive weeks) dose-dependently inhibits the growth of HCT-116 and SW480 xenografted SCID mice in vivo[1].
References:
[1]. Zhang Y, et al. A novel SRSF3 inhibitor, SFI003, exerts anticancer activity against colorectal cancer by modulating the SRSF3/DHCR24/ROS axis. Cell Death Discov. 2022 May 2;8(1):238.